Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Cash from Financing Activities (2020 - 2023)

Candel Therapeutics' Cash from Financing Activities history spans 4 years, with the latest figure at -$121000.0 for Q4 2023.

  • For Q4 2023, Cash from Financing Activities fell 436.11% year-over-year to -$121000.0; the TTM value through Dec 2023 reached -$121000.0, down 100.61%, while the annual FY2024 figure was $94.3 million, 78017.36% up from the prior year.
  • Cash from Financing Activities for Q4 2023 was -$121000.0 at Candel Therapeutics, down from $36000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $71.4 million in Q3 2021 and bottomed at -$121000.0 in Q4 2023.
  • The 4-year median for Cash from Financing Activities is $74000.0 (2021), against an average of $11.5 million.
  • The largest annual shift saw Cash from Financing Activities skyrocketed 17682.14% in 2022 before it crashed 436.11% in 2023.
  • A 4-year view of Cash from Financing Activities shows it stood at $29000.0 in 2020, then soared by 245951.72% to $71.4 million in 2021, then crashed by 99.95% to $36000.0 in 2022, then plummeted by 436.11% to -$121000.0 in 2023.
  • Per Business Quant, the three most recent readings for CADL's Cash from Financing Activities are -$121000.0 (Q4 2023), $36000.0 (Q4 2022), and $22000.0 (Q2 2022).